Insider Buying: CSL Limited (ASX:CSL) Insider Purchases 200 Shares of Stock

CSL Limited (ASX:CSL) insider Megan Clark bought 200 shares of CSL stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of A$250.06 ($159.27) per share, with a total value of A$50,012.00 ($31,854.78).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark bought 132 shares of CSL stock. The shares were bought at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Stock Performance

The firm has a market capitalization of $77.43 billion, a P/E ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a current ratio of 1.86, a quick ratio of 1.68 and a debt-to-equity ratio of 64.46.

CSL Increases Dividend

The business also recently announced a Interim dividend, which will be paid on Tuesday, April 8th. Investors of record on Tuesday, April 8th will be issued a dividend of $2.073 per share. This is an increase from CSL’s previous Interim dividend of $1.83. The ex-dividend date is Sunday, March 9th. This represents a dividend yield of 0.81%. CSL’s payout ratio is presently 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.